Clinical trials: SARS-COV2 Virus
COVID-19
A Study of the Investigational Monoclonal Antibody, VYD2311, in Healthy Participants
A study to investigate the safety, tolerability, and pharmacokinetics of a SARS-CoV-2-directed monoclonal antibody in healthy participants
- Trial name
- NCT06523153
- Testing
- VYD2311
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Invivyd, Inc.
SARS-CoV-2, Covid19
Clinical Evaluation of a COVID-19 Antigen Self-Test (CoviDx™)
Prospective study that will evaluate the clinical agreement of the CoviDx™ Self test compared to SARS-CoV-2 RT-PCR.
- Trial name
- CoviDx™ (NCT05403346)
- Testing
- CoviDx™ Covid-19 Antigen Self-Test
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Lumos Diagnostics
SARS-CoV-2 Virus Infection
Safety and Immunogenicity of VLA2001 Adults Aged ≥56 Years
This is a A Phase III, Open label, Multicenter, Single Arm Study to assess the Safety, Tolerability and Immunogenicity of VLA2001 in volunteers aged ≥ 56 years.
- Trial name
- NCT04956224
- Testing
- VLA2001
- Where
- 8 sites in New Zealand
- Volunteers
- 306 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
COVID-19 Pneumonia
Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stem Cells
Novel coronavirus disease COVID-19, produced by SARS-CoV-2, has become a health emergency around the world. Since first patients were detected in Wuhan (China), in December 2019, COVID-19 has spread quickly worldwide, being a…
- Trial name
- MSV-COVID (NCT04361942)
- Testing
- Mesenchymal Stem Cells (MSCs)
- Where
- Spain
- Volunteers
- 24 people
- Sponsor
- Red de Terapia Celular
COVID-19
Immunogenicity and Safety of Booster Immunization of ZF2001 After Inoculation With Two Doses of BBIBP-CorV
Study objectives: To evaluate the immunogenicity and immunity persistence and safety of recombinant novel coronavirus vaccine (CHO cells) after booster immunization in populations vaccinated with two doses of marketed novel…
- Trial name
- NCT05205083
- Testing
- Recombinant novel coronavirus vaccine (CHO cells)
- Where
- China
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
COVID-19, ARDS, Human
MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients
This study consists of two parts. Part A (Phase I): A Phase I Double-blind Randomized Placebo-controlled Study in Healthy Subjects to Assess the Safety, Pharmacokinetics, Pharmacodynamics of MRG-001 Part B (Phase 2): A Phase IIa…
- Conditions
- COVID-19, ARDS, Human, Stem Cells, Regeneration
- Trial name
- NCT04646603
- Testing
- MRG-001
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- MedRegen LLC
COVID-19, Long COVID
A Six-Month Follow-Up Study of Participants With Coronavirus Disease 2019 (COVID-19) Previously Enrolled in a RO7496998 (AT-527) Study
This study will evaluate the long-term sequelae of COVID-19 in patients diagnosed with COVID-19 who previously enrolled in a RO7496998 (AT-527) study (i.e.
- Trial name
- MEADOWSPRING (NCT05059080)
- Where
- 35 sites in Argentina, Belgium and 8 more
- Volunteers
- 72 people
- Sponsor
- Hoffmann-La Roche
Coronavirus Infection, COVID-19
Clinical Study of the Safety and Immunogenicity of a Recombinant Viral Vector AAV5 (Adeno-Associated Virus Type 5 )-RBD (Receptor Binding Domain)-S Vaccine for the Prevention of Coronavirus Infection (COVID-19)
A randomized, double-blind, placebo-controlled, adaptive, seamless phase I / II clinical study of the safety and immunogenicity of a recombinant viral vector AAV5-RBD-S vaccine for the prevention of coronavirus infection…
- Trial name
- COVER (NCT05037188)
- Testing
- Low dose BCD-250 injection, High dose BCD-250 injection, Low dose or high dose BCD-250 injection
- Where
- 2 sites in Russia
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Biocad
SARS-CoV2 Infection
Evaluation of Efficacy, Safety and Immunogenicity of GX-19N in Healthy Individuals Who Have Received COVID-19 Vaccines
The purpose of this study is to evaluate the efficacy, safety and immunogenicity of GX-19N in healthy individuals who have received one of COVID-19 vaccine authorized for emergency use.
- Trial name
- NCT05067946
- Testing
- GX-19N
- Volunteers
- healthy volunteers welcome
- Sponsor
- Genexine, Inc.
SARS-CoV-2 Infection, COVID-19
Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults
This is a Phase 1/2, randomized, placebo-controlled, and observer-blind study in healthy Japanese adults. The study will evaluate the safety, tolerability, and immunogenicity of the SARS-CoV-2 RNA vaccine candidate against…
- Trial name
- NCT04588480
- Testing
- BNT162b2
- Where
- 2 sites in Japan
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
COVID-19
Study of a Recombinant Spike COVID-19 Vaccine With Matrix-M in Older Adults and People at Increased Risk of Severe COVID-19
The purpose of this study is to evaluate the safety and immunogenicity of a single dose of Sanofi's Omicron subvariant-based Nuvaxovid in participants ≥ 65 years of age and participants 12 through 64 years of age who have at…
- Trial name
- NCT07861542
- Testing
- Omicron Subvariant-Based SARS-CoV-2 Recombinant Spike Vaccine Adjuvanted With Matrix-M
- Where
- 20 sites in United States
- Volunteers
- 660 people, healthy volunteers welcome
- Sponsor
- Sanofi
COVID-19, SARS-CoV-2
Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise
The purpose of this study is to evaluate the efficacy and safety of intravenous abatacept administered to hospitalized COVID-19 participants with respiratory compromise.
- Trial name
- NCT04472494
- Testing
- Abatacept
- Where
- 10 sites in United States, Puerto Rico
- Volunteers
- 61 people
- Sponsor
- Bristol-Myers Squibb
Coronavirus Disease-2019 (COVID-19)
Efficacy and Safety of TY027, a Treatment for COVID-19, in Humans
The emergence \& rapid spread of the coronavirus disease 2019 (COVID-19) since December 2019 across 188 countries globally has become a major public health crisis.
- Trial name
- NCT04649515
- Testing
- TY027, 0.9% saline
- Where
- Singapore
- Volunteers
- 17 people
- Sponsor
- Tychan Pte Ltd.
Coronavirus Disease 2019, Coronavirus Disease 2019 (COVID-19)
A Study of How Ibuzatrelvir is Taken up Into the Blood of Healthy Adults After Taking Different Tablets of Ibuzatrelvir
Healthy adults will be enrolled into this open-label, Phase 1 research study. Participants will spend about 9 nights and 10 days in the clinical research unit (CRU) and the total time in the study will be about 11 weeks.
- Conditions
- Coronavirus Disease 2019, Coronavirus Disease 2019 (COVID-19), COVID-19 (Coronavirus Disease 2019), Upper Respiratory Tract Infections
- Trial name
- NCT07552779
- Testing
- Ibuzatrelvir co-process API film coated tablet, Ibuzatrelvir filmcoated tablet
- Where
- Belgium
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Pfizer
Asthma, Chronic Obstructive Pulmonary Disease
Evaluation of the Efficacy of Respicure® (Resveratrol / Quercetin) in the Management of Respiratory Conditions Including Asthma,COPD and Long COVID.
Interventional, Prospective, National, Multicentre, Randomised, Open-label, Controlled Clinical Study Comparing Two Parallel Groups, One Control Arm (Standard Treatment) Versus Intervention Arm (Standard Treatment + Study…
- Conditions
- Asthma, Chronic Obstructive Pulmonary Disease, Long COVID
- Trial name
- NCT05601180
- Testing
- Respicure®, Standard of care
- Where
- 8 sites in Algeria
- Volunteers
- 402 people
- Sponsor
- Beker Laboratories
Healthy
Study to Investigate the Mass Balance, Metabolism, and Excretion of [14C]-PF-07304814 in Healthy Participants
This open-label, single dose study in approximately 5 healthy male and female (of non childbearing potential only) participants has been designed to characterize mass balance and further the understanding of human…
- Trial name
- NCT05050682
- Testing
- PF-07304814
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Pfizer
Post-COVID-19 Syndrome
Temelimab as a Disease Modifying Therapy in Patients With Neuropsychiatric Symptoms in Post-COVID 19 or PASC Syndrome
This study is a Phase 2, 24-week, randomized, prospective, double-blind, multicenter study in patients experiencing neuropsychiatric symptoms and functional impairment in the course of PASC.
- Trial name
- NCT05497089
- Testing
- Temelimab 54mg/kg
- Where
- 14 sites in Italy, Spain and 1 more
- Volunteers
- 203 people
- Sponsor
- GeNeuro SA
Covid-19, Sars-CoV2
Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19
This is a two-arm, open-label, randomized, phase 2, controlled center study to assess the safety and efficacy of Viusid and Asbrip in patients with mild to moderate symptoms of respiratory disease caused by 2019 coronavirus…
- Conditions
- Covid-19, Sars-CoV2, Diabete Mellitus, Cardiopathy
- Trial name
- NCT04407182
- Testing
- Viusid and Asbrip
- Where
- Ecuador
- Volunteers
- 60 people
- Sponsor
- Catalysis SL
Sars-CoV-2, Covid19
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects
BLD-2660 is a novel, synthetic, orally active, small molecule inhibitor of calpain (CAPN) 1, 2, and 9 that is selective over the cathepsins as well as other protease families, displays good metabolic stability and permeability…
- Trial name
- NCT04334460
- Testing
- BLD-2660
- Where
- 35 sites in United States, Brazil
- Volunteers
- 120 people
- Sponsor
- Blade Therapeutics
COVID-19
Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime-Boost Regimen for the Prevention of COVID-19
The objective is to evaluate the safety and immunogenicity of AZD1222 given in combination with (either before or after) rAd26-S, for the prevention of COVID 19 in adults ≥ 18 years of age.
- Trial name
- NCT04684446
- Testing
- AZD1222, rAd26-S
- Where
- 4 sites in Russia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- R-Pharm
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.